Whilst the overall market for Nuvaring (original and generics) appears to be shrinking, it's still a half a billion dollar plus annual market in the US. Even if Mayne took a very modest 10-20% market share, that's still $50-$100 million a year in additional revenue from one product. Separately, I wonder if Mithra/Mayne have pondered the possibility of a new and improved version of Nuvaring by substituting the plant-based estrogen from Nextstellis and creating a "natural ingredient" version of Nuvaring?
Ann: FDA approval of HALOETTE, a generic version of NUVARING, page-11
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.88 |
Change
-0.150(2.98%) |
Mkt cap ! $396.4M | |||
| Open | High | Low | Value | Volume |
| $5.03 | $5.03 | $4.87 | $728.7K | 147.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 2947 | $4.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.88 | 279 | 8 |
View Market Depth
| Last trade - 12.46pm 23/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |